iROM2: Immunomodulation With Eltrombopag in ITP
Study Details
Study Description
Brief Summary
The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
The randomized open lable study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary ITP. Treatment protocol will be HD-DXM (40 mg PO, day 1-4) with or without eltrombopag (25-50 mg PO, day 5-140) on an outpatient basis. Immunological investigations will be performed before start of treatment and then on week 3, 20 (end of therapy) and 30.
- Intervention phase:
Medical history and physical examination including assessment of severe bleeding every week until week 4, every second week until week 20. Complete blood count every week until week 10. For the adjustment of the Thrombopoietin receptor agonist (TPO-RA) dose - every second week until week 20. Immunologic panel at the beginning and at week 3 and 20.
- Follow-up:
Three clinical visits are scheduled in the follow-up including a complete blood count: at week 22, 24 and 30. Immunologic panel will be done at week 30 (end of study).
High-dose dexamethasone (HD-DXM) will be administered orally (40 mg) from day 1-4, followed by Arm 1 or 2 (1:1 randomization).
Arm 1: Standard Arm No planed further treatment. = standard therapy. In case of non-response after 2 courses of HD-DXM (week 4): cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2).
In case of relapse: repeat HD-DXM (40 mg day 1-4), up to a maximal of 3 courses. Time between 2 courses should be minimal 14 days. In case of re-relapse after the third course: cross-over to Arm 2: Start Eltrombopag (Revolade®), 50 mg PO until day 140 (details see Arm 2).
Arm 2: Study Arm Eltrombopag (Revolade®), 50 mg per os, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
In case of non-response after 4 weeks on eltrombopag: drop out
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Other: Standard Arm HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 1: No planed further treatment. = standard therapy (without eltrombopag) |
Drug: standard therapy (without eltrombopag): HD-DXM
standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
|
| Experimental: Study Arm HD-DXM will be administered orally (40 mg) from day 1-4, followed by Arm 2: The subjects in the experimental arm will be treated with eltrombopag: Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week (week 21) from day 141-148 with 50 mg every second day. Eltrombopag will be administered on a starting dose of 50mg. After the end of treatment a clinical and laboratory observation follow-up period until week 30 follows. |
Drug: Eltrombopag (Revolade®)
Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) indicated in patients with ITP refractory to first-line drugs or lasting more than 6 months. Administration of Eltrombopag (Revolade®), 50 mg PO, from day 5-140. Tapering over 1 week from day 141-148 with 50 mg every second day.
Drug: standard therapy (without eltrombopag): HD-DXM
standard therapy (without eltrombopag): HD-DXM administered orally (40 mg) from day 1-4
|
Outcome Measures
Primary Outcome Measures
- Change in percentual T-regulatory cells (Tregs) [before (Tregs/CD4), at week 3 and at the end of the treatment (week 20)]
Assessment of the percentage of Tregs (Tregs/CD4) in the study arm compared to the standard arm. The Tregs will be defined as CD4+CD25+ CD127+ in the fluorescence-activated cell sorting (FACS).
Secondary Outcome Measures
- Change in Th1/Th2 balance [at baseline and weeks 3, 20 and 30]
Change in Th1/Th2 balance will be performed by analysis of immunologic profile (immune cell characteristics, messenger ribonucleic acid (mRNA) of immune cells, cytokines, cytokine concentrations)
- Clinical response to eltrombopag therapy [trial duration (baseline to week 30)]
Clinical response to eltrombopag therapy (by assessing need of inpatient daycare and use of rescue treatment)
- Platelet response to eltrombopag [at baseline and weeks 6, 20 and 30]
Platelet response to eltrombopag: proportion of subjects achieving a platelet count of ≥50x109/l (complete response, response and no response;Response at each assessment is defined as a platelet count of ≥ 50x109/l).
Other Outcome Measures
- Number of Adverse Events [trial duration (baseline to week 30)]
Safety of eltrombopag analyzed by documentation of number of Adverse Events
- Severe bleeding [trial duration (baseline to week 30)]
Severe bleeding is defined as bleeding requiring hospital admission and/or blood transfusion.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Informed consent as documented by signature
-
Newly diagnosed primary ITP according to the definition of Rodeghiero et al. and a risk of platelet count of <30x109/l or risk of severe bleeding
-
First-line therapy maximum for 1 week prior to enrolment
-
Bleeding severity and quality of life are neither an inclusion nor an exclusion criterion.
Exclusion Criteria:
-
Patients previously treated for ITP more than 7 days prior to enrolment (e.g. Steroid, intravenous immunoglobulin (IVIG), platelet infusion)
-
Patients treated with second-line drugs prior to enrolment
-
Life-threatening bleeding (and inability to sign informed consent)
-
Secondary ITP
-
Positive family history for ITP
-
Presence or history of autoimmune disease as judged by the investigator
-
Hepatosplenomegaly in the clinical examination
-
Relevant hepatic disease as judged by the investigator
-
Presence or history of thromboembolic disease
-
Patients with splenectomy
-
Women who are pregnant or breast feeding
-
Intention to become pregnant during the course of the study
-
Lack of safe double contraception
-
Any vaccination 2 weeks prior start of the study
-
Immunsuppressive and antiplatelet drugs
-
Known or suspected non-compliance, drug or alcohol abuse
-
Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, incompetence to judge
-
Participation in another study with investigational drug within the 30 days preceding and during the present study
-
Enrolment of the investigator, his/her family members, employees and other dependent persons
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Aarau Cantonal Hospital, Division of Hematology | Aarau | Switzerland | ||
| 2 | University Children's Hospital Basel (UKBB) | Basel | Switzerland | 4031 | |
| 3 | University Hospital Basel, Division of Hematology | Basel | Switzerland | 4031 | |
| 4 | University Hospital Bern, Division of Hematology | Bern | Switzerland | ||
| 5 | Liestal Cantonal Hospital, Division of Hematology | Liestal | Switzerland | ||
| 6 | Lucerne Cantonal Hospital, Division of Hematology | Lucerne | Switzerland |
Sponsors and Collaborators
- University Children's Hospital Basel
- Stiftung zur Förderung medizinischer und biologischer Forschung
- Novartis Pharmaceuticals
- University of Erlangen-Nürnberg, Department of Biology
Investigators
- Principal Investigator: Alexandra Schifferli, Dr. med., University Children's Hospital Basel, UKBB
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2021-00044; ks19Schifferli